



ePAT validation tests successful

Highlights

- **Further validation test results have confirmed the excellent correlation between the ePAT App for dementia and a standard assessment commonly used in Australian aged care homes, the Abbey Pain Scale (APS).**
- **An additional 126 sets of paired data were obtained from 17 geriatric residents with moderate-to-severe dementia from one of the three aged care homes used in the validation studies**
- **ePAT App achieved demonstrated excellent correlation with the APS with a correlation co-efficient of approximately 0.9.**
- **The results of the validation tests have informed the design of a new version of the App to be released for further testing at the end of June 2016**

MinQuest Limited (ASX: MNQ) ("MinQuest" or "the Company") is pleased to announce Australian-based medical research company Electronic Pain Assessment Technology (ePAT) Pty Ltd ("ePAT") has successfully completed further validation testing of its revolutionary pain assessment App on a group of aged-care residents suffering dementia.

The validation studies involved 17 geriatric residents with moderate-to-severe dementia from three accredited Australian aged care homes in the Perth Metropolitan Area. The additional 126 matched pairs of data were analysed expanding the total dataset from all validation studies undertaken to date to 354 matched pairs.

The validation studies involved a clinical staff member of the aged care home undertaking pain assessments, as part of standard care of the resident, using the Abbey Pain Scale (APS) and a researcher repeating those assessments using the ePAT App.

Validation was then assessed on the basis of the correlation between matched pairs of APS versus ePAT pain intensity scores. The overall correlation coefficient achieved was in the range of 0.9.

ePAT chief executive officer Professor Jeff Hughes said the App successfully identified the presence and intensity of pain in all residents when compared to the use of APS, a standard assessment commonly used in residential aged care facilities.

"Excellent correlation was found when assessing pain at rest and on movement in those patients," Professor Hughes said.

"The ability of the App to discern between pain on movement and pain at rest was measured by comparing scores before and after a potentially painful event such as movement in walking, repositioning and toileting.

19 May 2016

DIRECTORS

Frank Terranova
Non- Executive Chairman

Jeremy Read
Managing Director

Paul Niardone
Non-Executive Director

Adam Davey
Non-Executive Director

Stephen Kelly
Company Secretary

SHARE INFORMATION

ASX Code: MNQ
Issued Capital:
296,805,545 Fully Paid
Shares
72,936,522 Listed Options
15,619,853 Unlisted Options


CONTACT INFORMATION

Registered Office:
Unit 1, 47 Park Road
Milton, QLD 4064
T: +61 7 3511 6570
F: +61 7 3369 3305
www.minquest.com.au

MEDIA ENQUIRIES

Colin Jacoby
Professional Public
Relations Pty Ltd
T: +61 8 9388 0944
M: + 61 411 828 073

MinQuest Limited
ACN: 146 035 127



“As expected, pain scores associated with movement were higher than those at rest in the same individual due to movement using more muscles and joints, thereby causing more pain.”

Professor Hughes said any association between pain scores was not influenced by the timing whether at rest or following movement.

Data from the validation studies is being used to refine the ePAT pain scale, and this will be incorporated into a new version of the ePAT App for Dementia due for release for testing at the end of June 2016. Validation studies for the new version of the App are planned to commence in July in two residential aged care homes in Perth.

The App, which is based on research developed by Curtin University over the past 3½ years, is being developed and rolled out in two phases; one for patients with dementia who have lost the ability to communicate with their carers and the second for young children who have not yet learnt to speak.

CSIRO ON Accelerator Program

ePAT is also pleased to provide an update on the CSIRO On Accelerator Program with Professor Hughes among other representatives from ePAT attending a week-long workshop in Sydney last week.

The workshop allowed members of the ePAT team to work with a series of mentors and coaches. At this particular workshop the key issues addressed and worked upon were:

- Pitching your story and focusing on the why do what you do, rather than the what and the how
- Identifying and validating channels to market
- Refinement of the value proposition and development of marketing strategies

As previously announced, ePAT has been selected as one of eleven teams from CSIRO and Australian universities to be a part of the latest round of the ON Accelerator program (refer to ASX announcement dated 26 April 2016).

The ON Accelerator is an intensive three-month program for successful researchers and their collaborators to develop and validate high potential commercial opportunities.

About ePAT

On 14 April 2016, MinQuest announced that it has entered in a binding heads of agreement to acquire 100% of the issued capital of ePAT. ePAT is developing revolutionary mobile medical applications that use facial recognition software to facilitate and improve pain assessment in patients that are unable to communicate (“App”). The App is being developed



and rolled out in two phases; one for patients with dementia who have lost the ability to communicate with their carers and the second for young children who have not yet learnt to speak. The ePAT Apps are being developed for the global market, initially for health care professionals and professional carers of patients with dementia and subsequently for parents and carers of young children. ePAT is anticipating obtaining any required regulatory approvals for the App for patients with dementia, to be classed as a medical device in Australia, by June 2017.

Forward Looking Statements

This announcement contains "forward-looking statements". Such forward-looking statements include, without limitation: proposed developments in the Company's business, estimates of future earnings, the sensitivity of earnings to commodity prices and foreign exchange rate movements; estimates of future production and sales; estimates of future cash flows, the sensitivity of cash flows to commodity prices and foreign exchange rate movements; statements regarding future debt repayments; estimates of future capital expenditures; estimates of resources and statements regarding future exploration results; and where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis. However, forward looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Such risks include, but are not limited to competition with the Company's business activities, changes in technology, the ability of the Company to obtain and maintain any required regulatory approvals for its current or proposed business activities, commodity price volatility, currency fluctuations, increased production costs and variances in resource or reserve rates from those assumed in the company's plans, as well as political and operational risks in the countries and states in which we operate or sell product to, and governmental regulation and judicial outcomes. For a more detailed discussion of such risks and other factors, see the Company's Annual Reports, as well as the Company's other filings. The Company does not undertake any obligation to release publicly any revisions to any "forward looking statement" to reflect events or circumstances after the date of this release, or to reflect the occurrence of unanticipated events, except as may be required under applicable securities law.